big recent developments (biotech), page-4

Robert Moses (Chairman) - ANP

Robert W (Bob) Moses, recently retired Vice President of CSL Limited, draws on more than 35 years in the pharmaceutical industry. For the past eight years, Bob's specific responsibilities have been focused on the growth and development of CSL's international businesses and global commercial relationships; first as General Manager International (1993-1997) and more recently as Corporate Vice President (1998-2001).

His accomplishments include negotiating commercial agreements and alliances with major multinational pharmaceutical and veterinary companies (for example Merck, Bayer and Astra), biotechnology companies (Aviron, Oravax, Pasteur Merieux, Chiron) and research institutions (Ludwig Institute, University of Queensland, University of Melbourne) as well as key roles in the acquisition and development of some of the company's international businesses.

Bob also played an important senior management role in strategic planning. Prior to joining CSL, he was Managing Director of commercial law firm, Freehills, Chairman and CEO of a NASDAQ-listed medical service company and Corporate Manager of New Business Development at ICI (now Orica). Bob also spent 17 years in various management roles at the multinational pharmaceutical company, Eli Lilly.

Since retiring from CSL, Bob has run a corporate consultancy, with clients including CSL, Thrombogenix and the Murdoch Children’s Research Institute.

He has an MBA from the University of Chicago and is a member of the American Management Association, the Australian Institute of Company Directors and the Australian Institute of Management. He is also a director of Meditech Limited.

I think he would have plenty of business relationships ready to go, should the compounds work successfully.

Jammin'.